Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”) today announced the presentation of six abstracts at
the European League Against Rheumatism (“EULAR”) 2019 Annual
Meeting being held June 12-15, 2019 in Madrid, Spain.
Summarized below are the abstract titles that
have been selected for oral or poster presentations. The EULAR
abstracts are available online at the conference website.
Information from the EULAR presentations are under embargo until
June 12, 2019. Once the posters are made public, they will be
available on the Company's website in the Scientific Conferences
section.
Oral Presentations:
Abstract #OP0069: Performance
of the American College of Rheumatology (ACR) Combined Response
Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score in
Phase 2 Trial of Lenabasum in diffuse Cutaneous Systemic Sclerosis
(dcSS)Oral Session: Myositis and SSc: Clinical
Highlights 2019Date and Time: June 12, 2018, 5:25
PM – 5:35 PM CETPresenting Author: Robert Spiera,
M.D., Director of the Vasculitis and Scleroderma Program at the
Hospital for Special Surgery, Weill Cornell Medical College in New
York City and Principal Investigator of the Phase 2 and Phase 3
studies in systemic sclerosis
Abstract #OP0241: Safety and
Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study
of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM)
Subjects Oral Session: SSc and Myositis – Novel
Therapeutic OptionsDate and Time: June 14, 2018,
10:40 AM – 10:50 AM CETPresenting Author: Victoria
Werth, M.D., Professor of Dermatology and Medicine at the
University of Pennsylvania Perelman School of Medicine and
Principal Investigator of Corbus' Phase 2 study in
Dermatomyositis
Abstract #OP0325: Safety and
Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study
in Diffuse Cutaneous Systemic Sclerosis Subjects (dcSSc)
Oral Session: Cannabis for arthritis: hype or
hope?Date and Time: June 14, 2018 at 4:45 PM –
4:55 PM CETPresenting Author: Robert Spiera, M.D.,
Director of the Vasculitis and Scleroderma Program at the Hospital
for Special Surgery, Weill Cornell Medical College in New York City
and Principal Investigator of the Phase 2 study in systemic
sclerosis
Poster Presentations:
Abstract #FRI0334: Performance
of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase
2 Trial with Lenabasum Date and Time: June 14,
2018 at 11:45 AM – 1:30 PM CETPresenting Author:
Ada Man, M.D., University of Manitoba Winnipeg, MB, Canada
Abstract #SAT0303: Design of
Phase 3 Study of Lenabasum for the Treatment of
DermatomyositisDate and Time: June 15, 2018 at
10:30 AM – 12:00 PM AM CETPresenting Author:
Victoria Werth, M.D., Professor of Dermatology and Medicine at the
University of Pennsylvania Perelman School of Medicine and
Principal Investigator of Corbus' Phase 3 study in
Dermatomyositis
Poster Tour:Abstract #FRI0307:
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces CD4 Cell
Populations and Downregulates Type 1 and 2 Interferon Activities in
Lesional Dermatomyositis Skin Poster Tour:
Clinical Science Highlights – SSc and MyositisDate and
Time: June 14, 2018 at 11:50 AM – 1:30 PM
CETPresenting Author: Kristen Chen, B.A.,
pre-doctoral fellow in the laboratory of Victoria Werth, M.D.,
Professor of Dermatology and Medicine at the University of
Pennsylvania Perelman School of Medicine
About Lenabasum
Lenabasum is a rationally-designed, oral, small
molecule that selectively binds as an agonist to the cannabinoid
receptor type 2 (CB2). CB2 is preferentially expressed on activated
immune cells, fibroblasts, muscle cells, and endothelial cells. In
both animal and human studies conducted to-date, lenabasum has
induced the production of Specialized Pro-resolving lipid Mediators
(“SPMs”) that activate endogenous pathways which resolve
inflammation and speed bacterial clearance without
immunosuppression. Lenabasum is also believed to have a direct
effect on fibroblasts to limit production of fibrogenic growth
factors and extracellular connective tissue that lead to tissue
fibrosis (scarring). Data from animal models and human clinical
studies suggest that lenabasum can reduce expression of genes and
proteins involved in inflammation and fibrosis. Lenabasum has
demonstrated promising activity in animal models of skin and lung
inflammation and fibrosis in systemic sclerosis (SSc). Lenabasum is
also active in animal models of lung infection and inflammation in
cystic fibrosis and joint inflammation and scarring in rheumatoid
arthritis.
Lenabasum has demonstrated an acceptable safety
and tolerability profiles in clinical studies to date. Lenabasum
treatment was associated with improvement in multiple
physician-assessed and patient-reported efficacy outcomes in Phase
2 studies in patients with diffuse cutaneous SSc and
skin-predominant dermatomyositis. ACR CRISS score was the primary
efficacy endpoint in the Phase 2 study of lenabasum in diffuse
cutaneous SSc and showed a greater treatment effect in subjects who
received lenabasum compared to placebo in that study. Lenabasum
treatment also was associated with a lower rate of and longer time
to pulmonary exacerbations in a Phase 2 cystic fibrosis study.
Additional clinical studies are being conducted and/or planned to
confirm these results and support applications for regulatory
approval.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its pipeline of endocannabinoid
system-targeting synthetic drug candidates. The Company's lead
product candidate, lenabasum, is a novel, synthetic, oral,
selective cannabinoid receptor type 2 (CB2) agonist designed to
resolve chronic inflammation and fibrotic processes. Lenabasum is
currently being evaluated in systemic sclerosis, cystic fibrosis,
dermatomyositis, and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug
candidates from more than 600 novel compounds targeting the
endocannabinoid system. The pipeline includes CRB-4001, a 2nd
generation, peripherally-restricted, selective cannabinoid receptor
type 1 (CB1) inverse agonist. Potential indications for CRB-4001
include NASH, among others. Corbus plans to start a Phase 1 study
of CRB-4001 in 2019, intended to be followed by a National
Institutes of Health (NIH)-funded proof-of-concept Phase 2
study.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617) 415-7745Email:
ir@corbuspharma.com
Lindsey Smith, Associate Director, Investor Relations and
Corporate CommunicationsPhone: +1 (617) 415-7749Email:
mediainfo@corbuspharma.com
Jenene ThomasJenene Thomas Communications, LLCPhone: +1 (833)
475-8247Email: crbp@jtcir.com
Source: Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024